46

Anju Software recently announced that Gustave Roussy, one of the top five cancer research centers in the world and Europe's top-ranked hospital for oncology research, has renewed its agreement to use the company's TrialMaster Electronic Data Capture (EDC) solution. Gustave Roussy has utilized TrialMaster successfully for the past five years to accelerate and drive oncology trial efficiencies across a myriad of clinical trial designs. The renewal of the contract with Gustave Roussy is a bellwether event for Anju Software according to Joe Alea, their head of Product Development and Management.

Anju Software is confident that their TrialMaster EDC technology is the most intuitive Electronic Data Capture (EDC) Suite on the market. TrialMaster EDC features superior usability and flexibility and is an ideal solution for Phase I-IV clinical trials, according to Mr. Alea. "It improves efficiencies and reduces workflow impact while enhancing your data quality, resulting in faster study submission times. TrialMaster 5.1 delivers a range of enhanced trial efficiency capabilities, highlighted by a unique company-created technology called Parameterized Edit Check that facilitates reuse of edit checks for flagging inaccurate data across multiple clinical trials."

Anju Software recently announced that Gustave Roussy continues to use the TrialMaster electronic data capture and clinical study data management platform. "With hundreds of oncology clinical trials, Gustave Roussy requires software that can manage the ever-expanding demands of clinical data management," Mr. Alea explains. "TrialMaster EDC provides Gustave Roussy researchers with flexible query management as well as sophisticated reporting and data visualization, enabling actionable insights that facilitate better trial oversight across a clinical organization."

The renewal of Gustave Roussy's TrialMaster EDC contract for five more years is a bellwether event for Anju Software, according to Mr. Alea. "The Anju TrialMaster EDC system has been pivotal to the expansion of our clinical work these past five years and is ideally suited to the complexities and risks of investigating new oncology compounds," said Stefan Michiels, Head of Department of Biostatistics and Epidemiology, Gustave Roussy. "We



collaboration with Anju as the TrialMaster platform technology develops further to meet the changing needs and requirements of cancer clinical research."

Gustave Roussy is classed as the leading European Cancer Centre and the fifth on the world stage. It is devoted entirely to patients who have cancer and caters to almost 50,000 patients per year. "It has been an honour for us to work with Gustave Roussy these past few years and witness TrialMaster's impact on driving cancer research programs that deliver innovative, new treatment options for the challenging needs of these patient populations," said Rohit Mistry, Senior Vice President, EMEA. "We are delighted to continue this vital work with our Gustave Roussy partners. Their confidence in Anju and TrialMaster validate our work and strengthen our commitment to delivering superior service for the benefit of cancer patients around the world."





Anju Software

Website: www.anjusoftware.com